|
|
|
||
(State or other jurisdiction of
incorporation) |
(Commission File Number)
|
(I.R.S. Employer
Identification No.) |
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
|
|
The
|
Item 3.01
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
Date: September 28, 2023
|
Atossa Therapeutics, Inc.
|
|||
By:
|
/s/ Greg Weaver
|
|||
Greg Weaver | ||||
Executive VP, Chief Financial Officer and Secretary
|
Document And Entity Information |
Sep. 26, 2023 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | Atossa Therapeutics, Inc. |
Document, Type | 8-K |
Document, Period End Date | Sep. 26, 2023 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 001-35610 |
Entity, Tax Identification Number | 26-4753208 |
Entity, Address, Address Line One | 107 Spring Street |
Entity, Address, City or Town | Seattle |
Entity, Address, State or Province | WA |
Entity, Address, Postal Zip Code | 98104 |
City Area Code | 206 |
Local Phone Number | 588-0256 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity, Emerging Growth Company | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | ATOS |
Security Exchange Name | NASDAQ |
Amendment Flag | false |
Entity, Central Index Key | 0001488039 |
RHY_U=3_ 102P,$% @ E(,\5Y>*NQS $P( L M !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/: (7->=I3W;+T]!;X"O.DQQ0FE(2S,. M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'36TGHX-R#8._AE8P=S8\?=_<#4$L#!!0 ( )2#/% &PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T. M@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4 M=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[N MF:*/Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF* M*I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04 " "4 M@SQ799!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0 MA:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS> MCQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[ ME.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8: M8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X M(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA M/UY_ 5!+ 0(4 Q0 ( )2#/%<'04UB@0 +$ 0 " M 0 !D;V-0 &UL4$L! A0#% @ E(,\5_#V'*3N M*P( !$ ( !KP &1O8U!R;W!S+V-O &UL4$L! A0# M% @ E(,\5YE $ & M @($-" >&PO=V]R:W-H965T &UL4$L! A0# M% @ E(,\5Y^@&_"Q @ X@P T ( !@ P 'AL+W-T M>6QE &PO=V]R:V)O;VLN>&UL4$L! A0#% M @ E(,\5R0>FZ*M ^ $ !H ( !LA$ 'AL+U]R96QS M+W=O 9(9 0 SP, M !, ( !EQ( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& / D "0 ^ @ X1, end